Quantum BioPharma Ltd.(QNTM)Earnings, Financials & Key Ratios
QNTM•NASDAQ
$5.01
$21M mkt cap·Price updated May 7, 2026
AboutQuantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$15M+3.9%
- Net Income-$27M-87.5%
- EPS (Diluted)-8.11+35.1%
- ROE-342.92%-181.9%
- ROIC-226.24%-47.3%
- Debt/Equity0.37+365.4%
- Interest Coverage-24.76+92.1%
QNTM Key Insights
Quantum BioPharma Ltd. (QNTM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
QNTM Price & Volume
Quantum BioPharma Ltd. (QNTM) stock price & volume — 10-year historical chart
Loading chart...
QNTM Growth Metrics
Quantum BioPharma Ltd. (QNTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-84.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM25.46%
Return on Capital
10 Years-98.72%
5 Years-117.48%
3 Years-149.43%
Last Year-200.67%
QNTM Recent Earnings
Quantum BioPharma Ltd. (QNTM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 6, 2026EPS
$3.06
Est $0.49
-524.0%
Revenue
—
Est $4M
Q2 2026
Mar 26, 2026EPS
$0.71
Est $1.02
+30.5%
Revenue
—
Est $2M
Q4 2025
Nov 7, 2025EPS
$1.25
Est $0.20
-525.0%
Revenue
—
Est $889,591
Q3 2025
Aug 6, 2025EPS
$3.23
Est $0.17
-1800.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $3.06vs $0.49-524.0% | —vs $4M |
| Q2 2026 | Mar 26, 2026 | $0.71vs $1.02+30.5% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $1.25vs $0.20-525.0% | —vs $889,591 |
| Q3 2025 | Aug 6, 2025 | $3.23vs $0.17-1800.0% | — |
Based on last 12 quarters of dataView full earnings history →
QNTM Peer Comparison
Quantum BioPharma Ltd. (QNTM) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ANVS | 61.74M | 2.27 | -1.62 | -0.68% | ||||
 NRXP | 84.71M | 3.06 | -2.28 | -157.28% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 CMPS | 902.25M | 9.39 | -3.05 | -335.93% | ||||
 ATAI | 964.15M | 4.01 | -4.31 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 LWAY | 390.55M | 25.64 | 28.81 | 13.74% | 6.52% | 17.25% | 0.00 |
Compare QNTM vs Peers
Quantum BioPharma Ltd. (QNTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QNTM Income Statement
Quantum BioPharma Ltd. (QNTM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -100% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 2.04M | 0 | 0 | 0 | 0 | 0 | 555.33K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 20.63K▲ 0% | 0▼ 100.0% | -1.84M▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -555.33K▲ 0% |
| Gross Margin % | 100% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -100% | - | 100% | - | - | - | - | - |
| Operating Expenses | 2.82M | 18.62M | 20.44M | 30.69M | 33.74M | 27.43M | 23.79M | 16.14M | 15.03M |
| OpEx % of Revenue | 13686.02% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.82M | 17.49M | 20.49M | 18.11M | 23.37M | 15.98M | 13.2M | 9.31M | 12.22M |
| SG&A % of Revenue | 13686.02% | - | - | - | - | - | - | - | - |
| Research & Development | 0 | 0 | 0 | 7.83M | 6.33M | 6.91M | 3.86M | 6.08M | 2.81M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 1.13M | -45.53K | 4.75M | 4.05M | 4.54M | 6.73M | 742.8K | 0 |
| Operating Income | -2.8M▲ 0% | 0▲ 100.0% | -22.48M▲ 0% | -30.69M▼ 36.5% | -33.74M▼ 9.9% | -27.43M▲ 18.7% | -23.79M▲ 13.3% | -16.14M▲ 32.2% | -15.59M▲ 3.4% |
| Operating Margin % | -13586.02% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 100% | - | -36.5% | -9.95% | 18.71% | 13.27% | 32.17% | 3.41% |
| EBITDA | -2.8M | -16.54M | -20.54M | -26.79M | -29.7M | -22.89M | -21.28M | -15.65M | -15.03M |
| EBITDA Margin % | -13586.02% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -9359.74% | -490.11% | -24.19% | -30.42% | -10.85% | 22.92% | 7.03% | 26.49% | 3.93% |
| D&A (Non-Cash Add-back) | 0 | 134.5K | 1.94M | 3.9M | 4.05M | 4.54M | 2.51M | 490.57K | 555.33K |
| EBIT | -2.8M | -16.67M | -33.93M | -28.22M | -33.87M | -26.65M | -18.23M | -14.87M | -15.59M |
| Net Interest Income | 0 | 0 | -155.32K | -231.89K | -68.11K | 318.91K | 786.06K | 525.31K | -389.25K |
| Interest Income | 0 | 0 | 0 | 3.69K | 1.29K | 367.74K | 786.36K | 572.89K | 240.22K |
| Interest Expense | 0 | 0 | 155.32K | 235.58K | 69.4K | 48.82K | 299 | 47.58K | 629.47K |
| Other Income/Expense | 0 | -16.67M | -11.6M | 2.24M | -194.3K | 725.95K | 5.56M | 1.22M | -11.84M |
| Pretax Income | -2.8M▲ 0% | -16.67M▼ 494.9% | -34.08M▼ 104.4% | -28.45M▲ 16.5% | -33.94M▼ 19.3% | -26.7M▲ 21.3% | -18.23M▲ 31.7% | -14.92M▲ 18.2% | -27.43M▼ 83.9% |
| Pretax Margin % | -13586.02% | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.8M▲ 0% | -16.67M▼ 494.9% | -39.13M▼ 134.7% | -31.8M▲ 18.7% | -35.29M▼ 11.0% | -23.61M▲ 33.1% | -17.9M▲ 24.2% | -14.2M▲ 20.7% | -26.63M▼ 87.5% |
| Net Margin % | -13586.02% | - | - | - | - | - | - | - | - |
| Net Income Growth % | -9359.74% | -494.91% | -134.67% | 18.73% | -10.96% | 33.1% | 24.17% | 20.66% | -87.52% |
| Net Income (Continuing) | -2.8M | -16.67M | -34.08M | -28.45M | -33.94M | -26.7M | -18.23M | -14.92M | -27.43M |
| Discontinued Operations | 0 | 0 | 0 | -3.35M | -1.35M | 3.1M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -327.5K | -1.04M | -1.82M |
| EPS (Diluted) | -27.75▲ 0% | -183.54▼ 561.4% | -360.45▼ 96.4% | -171.62▲ 52.4% | -65.63▲ 61.8% | -39.62▲ 39.6% | -29.39▲ 25.8% | -12.49▲ 57.5% | -8.11▲ 35.1% |
| EPS Growth % | -9468.97% | -561.41% | -96.39% | 52.39% | 61.76% | 39.63% | 25.82% | 57.5% | 35.07% |
| EPS (Basic) | -27.75 | -183.54 | -360.45 | -171.62 | -65.63 | -39.62 | -29.39 | -12.49 | -8.11 |
| Diluted Shares Outstanding | 101K | 90.85K | 108.56K | 185.29K | 537.62K | 595.88K | 609.06K | 1.14M | 3.29M |
| Basic Shares Outstanding | 101K | 90.85K | 108.56K | 185.29K | 537.62K | 595.88K | 609.06K | 1.14M | 3.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
QNTM Balance Sheet
Quantum BioPharma Ltd. (QNTM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.28M | 16.57M | 8.56M | 26.87M | 45.93M | 17.85M | 11.09M | 12.05M | 6.47M |
| Cash & Short-Term Investments | 3.77M | 15.52M | 5.97M | 17.52M | 35.42M | 17M | 3.51M | 7.2M | 6.17M |
| Cash Only | 3.77M | 15.52M | 5.97M | 17.52M | 35.26M | 16.98M | 2.76M | 6M | 1.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 158.04K | 23.19K | 756.1K | 1.2M | 4.27M |
| Accounts Receivable | 234.2K | 727.58K | 1.56M | 161.34K | 500.96K | 374.38K | 7.42M | 3.81M | 230.63K |
| Days Sales Outstanding | 4.14K | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 709.37K | 0 | 0 | 0 | 0 | 117.24K | 52.04K |
| Days Inventory Outstanding | - | - | 126.96 | - | - | - | - | - | 34.2 |
| Other Current Assets | 0 | 0 | 0 | 8.61M | 8.65M | 0 | 0 | 861.23K | 13.07K |
| Total Non-Current Assets | 6.59M | 22.18M | 34.66M | 15.1M | 17.03M | 20.56M | 6.39M | 5.07M | 4.67M |
| Property, Plant & Equipment | 6.59M | 8.91M | 8.98M | 0 | 168.31K | 260.93K | 120.42K | 130.38K | 169.04K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 16.82M | 13.42M | 16.2M | 12.04M | 5.36M | 4.93M | 4.5M |
| Long-Term Investments | 0 | 13.26M | 8.86M | 1.68M | 660.23K | 827.61K | 6.05K | 2.22K | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 7.43M | 907.37K | 0 | 0 |
| Total Assets | 10.88M▲ 0% | 38.75M▲ 256.2% | 43.22M▲ 11.5% | 41.97M▼ 2.9% | 62.96M▲ 50.0% | 38.41M▼ 39.0% | 17.47M▼ 54.5% | 17.12M▼ 2.0% | 11.14M▼ 34.9% |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - |
| Asset Growth % | 152321.03% | 256.19% | 11.53% | -2.89% | 50.03% | -39% | -54.51% | -2.03% | -34.92% |
| Total Current Liabilities | 1.01M | 1.28M | 6.83M | 5.58M | 8.7M | 7.83M | 4.57M | 6.68M | 6.05M |
| Accounts Payable | 1.01M | 1.28M | 3.36M | 2.06M | 3M | 2.76M | 3.24M | 3.25M | 0 |
| Days Payables Outstanding | - | - | 601.54 | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 1.44M | 384.65K | 300.55K | 300.55K | 300.55K | 771.14K | 1.87M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M | 0 |
| Other Current Liabilities | 0 | 0 | 1.99M | 1.61M | 811.43K | 243.59K | 31.34K | 492K | 4.17M |
| Current Ratio | 4.26x | 12.94x | 1.25x | 4.82x | 5.28x | 2.28x | 2.43x | 1.80x | 1.07x |
| Quick Ratio | 4.26x | 12.94x | 1.15x | 4.82x | 5.28x | 2.28x | 2.43x | 1.79x | 1.06x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 110.33K | 79.12K | 131.04K | 38K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 110.33K | 79.12K | 131.04K | 38K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.01M | 1.28M | 6.94M | 5.66M | 8.83M | 7.87M | 4.57M | 6.68M | 6.05M |
| Total Debt | 0 | 0 | 1.59M | 510.61K | 555.9K | 516.42K | 339.2K | 824.92K | 1.87M |
| Net Debt | -3.77M | -15.52M | -4.38M | -17.01M | -34.7M | -16.46M | -2.42M | -5.17M | -29.09K |
| Debt / Equity | - | - | 0.04x | 0.01x | 0.01x | 0.02x | 0.03x | 0.08x | 0.37x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -218.43x | -119.77x | -487.99x | -545.96x | -60970.87x | -312.50x | -24.76x |
| Total Equity | 9.87M▲ 0% | 37.47M▲ 279.5% | 36.28M▼ 3.2% | 36.31M▲ 0.1% | 54.13M▲ 49.1% | 30.54M▼ 43.6% | 12.91M▼ 57.7% | 10.44M▼ 19.1% | 5.09M▼ 51.2% |
| Equity Growth % | 18280.87% | 279.55% | -3.18% | 0.09% | 49.09% | -43.58% | -57.73% | -19.13% | -51.21% |
| Book Value per Share | 97.74 | 412.42 | 334.18 | 195.95 | 100.69 | 51.26 | 21.20 | 9.18 | 1.55 |
| Total Shareholders' Equity | 9.87M | 37.47M | 36.28M | 36.31M | 54.13M | 30.54M | 13.24M | 11.48M | 6.91M |
| Common Stock | 10.34M | 49.87M | 73.74M | 103.21M | 152.32M | 143.41M | 137.78M | 150.47M | 169.39M |
| Retained Earnings | -3.35M | -19.46M | -59.07M | -90.87M | -126.15M | -144.16M | -157.91M | -172.11M | -197.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -84.78K | 207.8K | 239.61K | 652.6K | 417.34K | 50.8K | 101.36K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -327.5K | -1.04M | -1.82M |
QNTM Cash Flow Statement
Quantum BioPharma Ltd. (QNTM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -119.18K | -13.58M | -13.71M | -19.13M | -20.75M | -28.33M | -10.83M | -6.88M | -8.38M |
| Operating CF Margin % | -577.69% | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -337.53% | -11290.84% | -1.01% | -39.51% | -8.45% | -36.57% | 61.79% | 36.49% | -21.88% |
| Net Income | -2.81M | -16.67M | -34.08M | -28.45M | -33.94M | -26.7M | -18.23M | -14.92M | -26.63M |
| Depreciation & Amortization | 0 | 134.13K | 1.94M | 3.9M | 4.05M | 4.53M | 2.51M | 490.57K | 555.33K |
| Stock-Based Compensation | 2.38M | 4.73M | 12.08M | 8.05M | 7.44M | 1.53M | 3.84M | 152.21K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -1.52M | 5.24M | -3.44M | -1.19M | -575.13K | -576.27K | -2.36M | 15.68M |
| Working Capital Changes | 305.41K | -242.37K | 1.1M | 807.14K | 2.89M | -7.12M | 1.64M | 9.76M | 2.02M |
| Change in Receivables | -217.72K | -487.95K | -387.84K | 435.18K | -106.88K | -7.22M | -728.72K | 4.52M | 1.72M |
| Change in Inventory | 0 | 0 | -721.86K | 0 | 0 | 0 | 0 | -117.24K | 66.25K |
| Change in Payables | 790.97K | 318.46K | 825.12K | 0 | 0 | 0 | 0 | 0 | 1.2M |
| Cash from Investing | -6.09M | -7.34M | -230.89K | 6.51M | 268.96K | 12.12M | -269.58K | -1.5M | -1.99M |
| Capital Expenditures | -6.09M | -2.96M | -408.89K | 0 | -500K | -113.96K | 0 | 0 | 0 |
| CapEx % of Revenue | 29502.01% | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 1.5M | 1.75K | 0 | 768.96K | 0 | 31.78K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -286.06K | 36.62K | 0 | -250K | 0 | 0 | 0 |
| Cash from Financing | 9.95M | 32.95M | 4.01M | 24.17M | 38.21M | -2.07M | -3.13M | 11.62M | 6.21M |
| Debt Issued (Net) | 0 | 0 | -42.28K | -986.64K | -129.32K | -143.07K | -189.05K | 948.25K | 5.24M |
| Equity Issued (Net) | 10.96M | 33.03M | 3.43M | 25.1M | 38.34M | -1.93M | -2.96M | 10.67M | 538.95K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -1.93M | -2.96M | 0 | 0 |
| Other Financing | -1.01M | -81.68K | 622.59K | 59.55K | 0 | 0 | 20.25K | 0 | 424.1K |
| Net Change in Cash | 3.75M▲ 0% | 12.04M▲ 221.4% | -9.93M▼ 182.5% | 11.56M▲ 216.4% | 17.73M▲ 53.5% | -18.28M▼ 203.1% | -14.22M▲ 22.2% | 3.24M▲ 122.8% | -4.09M▼ 226.3% |
| Free Cash Flow | -6.21M▲ 0% | -16.54M▼ 166.5% | -14.01M▲ 15.3% | -19.13M▼ 36.6% | -21.25M▼ 11.1% | -28.7M▼ 35.1% | -10.83M▲ 62.3% | -6.88M▲ 36.5% | -8.38M▼ 21.9% |
| FCF Margin % | -30079.69% | - | - | - | - | - | - | - | - |
| FCF Growth % | -22681.94% | -166.48% | 15.3% | -36.59% | -11.06% | -35.07% | 62.27% | 36.49% | -21.88% |
| FCF per Share | -61.44 | -182.02 | -129.02 | -103.25 | -39.52 | -48.16 | -17.78 | -6.05 | -2.55 |
| FCF Conversion (FCF/Net Income) | 0.04x | 0.81x | 0.35x | 0.60x | 0.59x | 1.20x | 0.60x | 0.48x | 0.31x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QNTM Key Ratios
Quantum BioPharma Ltd. (QNTM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -57.1% | -70.44% | -106.12% | -87.62% | -78.03% | -55.76% | -82.4% | -121.65% | -342.92% |
| Return on Invested Capital (ROIC) | - | -69.6% | - | -62.63% | -89.93% | -130.72% | -122.8% | -145.24% | -153.57% | -226.24% |
| Gross Margin | - | 100% | - | - | - | - | - | - | - | - |
| Net Margin | - | -13586.02% | - | - | - | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.04x | 0.01x | 0.01x | 0.02x | 0.03x | 0.08x | 0.37x |
| Interest Coverage | - | - | - | -218.43x | -119.77x | -487.99x | -545.96x | -60970.87x | -312.50x | -24.76x |
| FCF Conversion | 0.92x | 0.04x | 0.81x | 0.35x | 0.60x | 0.59x | 1.20x | 0.60x | 0.48x | 0.31x |
| Revenue Growth | - | - | -100% | - | - | - | - | - | - | - |
QNTM Frequently Asked Questions
Quantum BioPharma Ltd. (QNTM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Quantum BioPharma Ltd. (QNTM) grew revenue by 0.0% over the past year. Growth has been modest.
Quantum BioPharma Ltd. (QNTM) reported a net loss of $26.2M for fiscal year 2025.
Dividend & Returns
Quantum BioPharma Ltd. (QNTM) has a return on equity (ROE) of -342.9%. Negative ROE indicates the company is unprofitable.
Quantum BioPharma Ltd. (QNTM) had negative free cash flow of $8.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More QNTM
Quantum BioPharma Ltd. (QNTM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates